• 01.11.2019 – 10:16

  REstore

  RESTORE 1st Advanced Therapies Science Meeting

  Berlin (ots/PRNewswire) - 25th-26th November 2019, Berlin RESTORE-Health by Advanced Therapies invites you to join the First Advanced Therapies Science Meeting (ATSM), an EACCME® accredited event, which will be held at the Maritim Hotel, Stauffenbergstraße in Berlin from the 25th - 26th November 2019. Advanced Therapies are one of the most recent and significant advances in medicine. They include gene and cell therapies ...

  more

• 21.10.2019 – 11:11

  Galderma

  Face Up To Rosacea: Galderma Launches Online Support to Empower and Equip Rosacea Sufferers to Discuss the True Burden of Their Disease With a Dermatologist

  Lausanne, Switzerland (ots/PRNewswire) - New 'Face up to rosacea' campaign comprising online content and a downloadable, personalized patient appointment guide, equips people living with the distressing skin disease to seek expert support to help break the cycle of rosacea and aim for long-term treatment success ...

  more

• 18.06.2019 – 12:37

  HiDoc Technologies GmbH

  

  5

  Berlin-based Digital Health Company Cara Care Raises $7M Series A Led by Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and Asabys Partners

  more

  Our press section

  One document

• 30.05.2019 – 10:01

  Merck KGaA

  Merck Pioneers New Efforts to See MS From the Inside Out

  Darmstadt, Germany (ots/PRNewswire) - Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate ...

  more

• 30.08.2011 – 09:04

  Astellas Pharma Europe Limited

  Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe

  Staines, England (ots/PRNewswire) - Astellas Pharma Inc. [http://www.astellas.com/en/corporate ] today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency. ...

  more